

<u>Business name</u>	<u>In cooperation with</u>	<u>Products marketed</u>	<u>Future trends</u>
		on the market from the fall of 1988 and 300 or more have been sold mainly to research laboratories.	methods have not been largely eroded. This is becoming a special type of study that is emphasized in study centres. 3) It is not as if actual items have already been targeted in terms of marketing of <u>in-vitro</u> diagnostic drugs and some are being marketed.
Eiken Kagaku	Company's own technology	Development is proceeding on a DNA probe diagnosis kit for typing of tuberculosis and marketing is anticipated. Type evaluation is performed after 2-3 weeks of cultivation. It is impossible to directly evaluate without cultivation with current sensitivity	1) The only significance is for tuberculosis on a commercial basis in terms DNA probe diagnosis. Even though there have been sales approaches from other companies, other items are being dismissed. 2) Optimum regions of amplification for each bacterium and virus must be researched in order to apply amplification by the PCR method and this is too costly.
Fuji Rebio	Tropix Co (U.S.) Seller of DNA probe diagnostic drugs Acquisition of shares	Diagnostic kits that use AMPPD labeling are under development by Tropix. Sensitivity is the same or better than that of isotope labeling.	1) Research will not be limited to use of AMPPD for only DNA probe diagnostics. 2) In order to increase popularity of DNA probes, development of an automated device is essential. Companies are competing in secret development. 3) Although HLA and ATL have been the targets for some period of time, they are not being opposed at the present time.
Fujisawa Pharmaceutical Co.	Onco (U.S.) Cosmo Bio. handles only probes	Sample distribution of DNA probe kits for HPV is anticipated (shortly).	1) Marketing as an <u>in-vitro</u> diagnostic drug is anticipated. There are plans for a type that carry screening a step further to group results into the 3 groups